Variable name;level;Overall;No;Yes;p;test
;n;1357;744;612;;
Age;[0 -40);801;382 (47.7);419 (52.3);<0.001;
;40+;554;361 (65.2);193 (34.8);;
Age (mean);;38.7 [34.9, 41.6];39.7 [36.0, 42.0];37.5 [33.7, 40.7];<0.001;nonnorm
Number of children;0;373;172 (46.2);200 (53.8);<0.001;
;1;279;153 (54.8);126 (45.2);;
;More than 1;705;419 (59.4);286 (40.6);;
BMI;<18.5;79;45 (57);34 (43);0.324;
;25-29.9;257;127 (49.6);129 (50.4);;
;>=30;107;56 (52.3);51 (47.7);;
;18.5-24.9;807;451 (55.9);356 (44.1);;
BMI (mean);;22.6 [20.5, 25.5];22.5 [20.4, 25.2];22.8 [20.5, 25.9];0.145;nonnorm
Treatment center;Curie Paris;818;421 (51.5);397 (48.5);NaN;
;Curie St Cloud;538;323 (60);215 (40);;
;Others;0;0 (NaN);0 (NaN);;
Genetic Analysis;No;656;413 (63);243 (37);<0.001;
;Yes;701;331 (47.3);369 (52.7);;
Hereditary predisposition;No;547;252 (46.2);294 (53.8);0.472;
;Yes;140;70 (50);70 (50);;
Inflammatory BC;No;1338;744 (55.6);594 (44.4);<0.001;
;Yes;18;0 (0);18 (100);;
Clinical Tumor size (mm);;30.3 (21.7);20.4 (16.0);42.1 (21.8);<0.001;
Clinical N stage (TNM);N0;854;540 (63.2);314 (36.8);<0.001;
;N1-N2-N3;492;195 (39.6);297 (60.4);;
SBR grade;Grade I-II;586;378 (64.5);208 (35.5);<0.001;
;Grade III;760;358 (47.1);402 (52.9);;
Histological type;NST;1265;666 (52.6);599 (47.4);<0.001;
;Lobular;54;50 (92.6);4 (7.4);;
;Others;36;27 (75);9 (25);;
Chemotherapy setting;NAC;611;0 (0);611 (100);NaN;
;Adjuvant;744;744 (100);0 (0);;
;NAC and adjuvant;0;0 (NaN);0 (NaN);;
;Chemotherapy without surgery;1;0 (0);1 (100);;
;No;0;0 (NaN);0 (NaN);;
Fertility preservation discussion;No;909;543 (59.7);366 (40.3);<0.001;
;Yes;447;201 (45);246 (55);;
